Neuropace Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.21
- Today's High:
- $7.965
- Open Price:
- $7.3
- 52W Low:
- $1.22
- 52W High:
- $9.5
- Prev. Close:
- $7.21
- Volume:
- 78052
Company Statistics
- Market Cap.:
- $230.93 million
- Book Value:
- 0.822
- Revenue TTM:
- $54.93 million
- Operating Margin TTM:
- -65.96%
- Gross Profit TTM:
- $32.49 million
- Profit Margin:
- -77.25%
- Return on Assets TTM:
- -20.51%
- Return on Equity TTM:
- -114.48%
Company Profile
Neuropace Inc had its IPO on 2021-04-22 under the ticker symbol NPCE.
The company operates in the Healthcare sector and Medical Devices industry. Neuropace Inc has a staff strength of 169 employees.
Stock update
Shares of Neuropace Inc opened at $7.3 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.21 - $7.97, and closed at $7.74.
This is a +7.35% increase from the previous day's closing price.
A total volume of 78,052 shares were traded at the close of the day’s session.
In the last one week, shares of Neuropace Inc have slipped by -13.33%.
Neuropace Inc's Key Ratios
Neuropace Inc has a market cap of $230.93 million, indicating a price to book ratio of 1.0097 and a price to sales ratio of 0.9055.
In the last 12-months Neuropace Inc’s revenue was $54.93 million with a gross profit of $32.49 million and an EBITDA of $-36021000. The EBITDA ratio measures Neuropace Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Neuropace Inc’s operating margin was -65.96% while its return on assets stood at -20.51% with a return of equity of -114.48%.
In Q2, Neuropace Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 61.9%.
Neuropace Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.51 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neuropace Inc’s profitability.
Neuropace Inc stock is trading at a EV to sales ratio of 0.6119 and a EV to EBITDA ratio of -0.7258. Its price to sales ratio in the trailing 12-months stood at 0.9055.
Neuropace Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $102.23 million
- Total Liabilities
- $11.51 million
- Operating Cash Flow
- $5.30 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Neuropace Inc ended 2024 with $102.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $102.23 million while shareholder equity stood at $21.23 million.
Neuropace Inc ended 2024 with $0 in deferred long-term liabilities, $11.51 million in other current liabilities, 26000.00 in common stock, $-490352000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.86 million and cash and short-term investments were $63.57 million. The company’s total short-term debt was $1,519,000 while long-term debt stood at $54.85 million.
Neuropace Inc’s total current assets stands at $86.51 million while long-term investments were $0 and short-term investments were $55.72 million. Its net receivables were $10.88 million compared to accounts payable of $1.81 million and inventory worth $10.01 million.
In 2024, Neuropace Inc's operating cash flow was $5.30 million while its capital expenditure stood at $0.
Comparatively, Neuropace Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.74
- 52-Week High
- $9.5
- 52-Week Low
- $1.22
- Analyst Target Price
- $6.9
Neuropace Inc stock is currently trading at $7.74 per share. It touched a 52-week high of $9.5 and a 52-week low of $9.5. Analysts tracking the stock have a 12-month average target price of $6.9.
Its 50-day moving average was $5.23 and 200-day moving average was $4.1 The short ratio stood at 6.33 indicating a short percent outstanding of 0%.
Around 855% of the company’s stock are held by insiders while 8708.2% are held by institutions.
Frequently Asked Questions About Neuropace Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company’s RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.